Class III & most Class IIb implantables
Certain established Class IIb implantable categories are excluded from this group under Article 120(3a)(a).

EU MDR compliance & European market access
Regulatory strategy, clinical evidence and quality support for Class IIb and III medical devices. Work directly with SYBEY Medtech to clarify your pathway, address critical gaps and prepare for your next regulatory milestone.
30+ years of founder experience · EU MDR transition leadership · PRRC responsibilities
Successful EU market access depends on a clear regulatory route, appropriate clinical evidence and a quality system that works in practice. When these elements are disconnected, submissions can stall and commercial plans become harder to deliver.
SYBEY Medtech brings quality, regulatory and clinical priorities together. Whether you are entering Europe for the first time, transitioning a legacy device or responding to notified body questions, we help define the work that matters and support your team through it.
For eligible legacy devices, the transition dates below depend on conditions already met and continued compliance. They are not a general extension for every manufacturer.
Certain established Class IIb implantable categories are excluded from this group under Article 120(3a)(a).
Includes sterile or measuring Class I devices and qualifying devices newly requiring notified body involvement under MDR.
Focused expertise across the core requirements, with support shaped around your current position and next milestone.
Clarify device qualification, classification and conformity assessment. Identify the regulatory obligations, responsibilities and milestones relevant to your EU market-entry plan.
Review the consistency of intended purpose, device claims, risk management and supporting evidence. Prioritize gaps against applicable MDR requirements and the GSPRs.
Align clinical evaluation and post-market clinical follow-up with your device and its claims. Identify evidence gaps, justification needs and priorities for additional data.
Connect quality processes with MDR obligations. Prepare for assessment, organise responses to notified body questions and coordinate remediation with the teams involved.
When timing is critical
A blocked submission, an unresolved clinical question or a capacity gap needs a clear response. SYBEY helps assess the issue, prioritize corrective work and establish owners and milestones. Scope, availability and timing are agreed after an initial review.
Our founder’s career spans Quality, Regulatory and Clinical Affairs for high-risk Class IIb and III medical devices.
Experience directing an MDR transition and coordinating the regulatory, quality and clinical work behind it.
Submissions overseen across international markets, alongside experience in EU MDR, US FDA and China NMPA requirements.
PRRC responsibilities, executive committee experience and leadership of a 30-person global department.
Regulatory decisions connect to clinical evidence, quality processes and responsibilities throughout the life of your device.
Understand your situation. Discuss your device, current regulatory status, principal challenge and target timing.
Agree the scope. Define the review, advisory or delivery support required, with clear priorities, responsibilities and terms.
Build the action plan. Assess the relevant documentation and evidence, identify critical gaps and sequence the work.
Support delivery. Work with your team on the agreed actions, responses and decisions needed for the next milestone.
SYBEY Medtech brings together executive-level strategic insight and hands-on experience across Quality, Regulatory and Clinical Affairs in complex medical device environments.
Our expertise spans EU MDR transitions, international regulatory submissions, PRRC responsibilities and strategic regulatory leadership.
We support manufacturers in translating complex requirements into clear decisions, actionable priorities and effective pathways to market access.
Let’s discuss your EU MDR priorities
Share a short overview of your device, regulatory status, main challenge and target timing. We will then discuss the appropriate scope of support and the next step.
contact@sybey-medtech.com · +33 6 99 84 97 08 · Use our contact page
Yes. The starting point is your device, intended purpose, classification and available evidence. The work can cover the regulatory pathway, conformity assessment, documentation and quality requirements, together with authorised representative and importer arrangements where applicable.
No. They concern specified legacy devices that meet the transitional conditions. New devices generally need to complete the applicable MDR conformity assessment before EU market placement. Your classification, certificate history and eligibility should be checked individually.
Yes. Support can focus on understanding the findings, assessing evidence gaps, structuring a response and coordinating remediation. The first review establishes the priorities and the scope of work; availability and timing are confirmed directly.
Yes. Support may begin with a defined review, a specific regulatory issue or a readiness assessment. Ongoing advisory or fractional executive support can be discussed where broader leadership is needed.
No. SYBEY provides advisory and implementation support. Conformity assessment decisions remain with the responsible notified body where required, and manufacturers retain their regulatory responsibilities.